A study led by scientists at the Hebrew University of Jerusalem in Israel has found that the cannabis plant contains two powerful compounds that may reverse fatty liver disease in mice without causing any intoxication. The study found that CBD (cannabidiol) and CBG (ceannabigerol) can improve blood sugar control, reduce liver fat, and lower blood lipid levels in obese mice. These results were largely independent of classical cannabinoid receptors. Daily injections of either CBD or CBG into the abdomen of mice increased the production of phosphocreatine, a form of creatine released by the liver to replenish energy supplies and maintain cellular health. This discovery highlights these compounds as promising therapeutic agents for metabolic dysfunction-associated steatotic liver disease (MASLD), a serious liver condition.